ClinicalTrials.gg
WithdrawnNCT03281694Updated Nov 6, 2024

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

A Phase 1 interventional study of Placebo and Nicotine in Cognitive Change, sponsored by University of Maryland, Baltimore. Withdrawn. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by University of Maryland, Baltimore · Phase 1, Interventional, and Basic science

How we know

Why this study was withdrawn
Drug supplier did not come through.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
21 Years to 50 Years
Sex
All
01

Study summary

Single-center, randomized, double-blind, placebo-controlled, proof-of-principle study to evaluate potential cognitive benefits of a single oral dose of AVL-3288 (3 mg) in the presence and absence of transdermal nicotine (7 mg/24 hrs) in healthy non-smokers, while monitoring the safety and tolerability of AVL-3288.

Read the detailed description

Nicotinic acetylcholine receptor (nAChR) agonists such as nicotine have been shown to enhance cognitive performance, especially functions in the attention domain. Efforts have been made to develop similar compounds as therapeutic agents for disorders such as schizophrenia or Alzheimer's disease. Over the last two decades, drug development has invested into novel nAChR agonists. Effects have generally been in the expected direction, but tended to be of small magnitude. A potential way of increasing the effect size ceiling is by co-administering a nAChR positive allosteric modulator (PAM). PAMs generally do not activate the nAChR on their own but bind to a second, modulatory site and facilitate agonist-induced responses. The present study is aimed at testing the effects of AVL-3288, a PAM selective for the α7 nAChR subtype that is thought to be of particular relevance for cognition in schizophrenia, on cognitive task performance, and on nicotine-induced improvements in cognitive task performance, in healthy adult non-smokers.

The aim of the present study is to provide the proof-of-principle that the attention-enhancing effects of the prototypical nAChR agonist nicotine can be potentiated by an α7 nAChR PAM (AVL-3288). Potentiation of nAChR agonist effects by PAMs have been shown in preclinical behavioral assays. The availability of AVL-3288 as a safe pure nAChR PAM for human research allows testing the hypothesis that nicotine and AVL-3288 will have additive or synergistic effects, such that the attention-enhancing effects of nicotine and AVL-3288 combined will be greater than the effects of either drug alone.

AVL-3288 has shown preclinical efficacy in rat paradigms of attention and memory, including models of cognitive dysfunction1-3. A human study in healthy adults reported no adverse effects associated with AVL-3288, tested at doses of 3, 10, and 30 mg. Some of the participants tested with 3 mg were smokers, some on nicotine replacement.

The present study will adopt a repeated measures design, in which a single group of 24 healthy non-smokers will complete 4 test sessions, in each of which they perform the same three cognitive paradigms. In each session, a skin patch will be administered 5 hrs prior to testing, and a solution (3 mL) will be administered by mouth 1 hr prior to testing. The skin patch is either a 7 mg/24 hrs nicotine patch or a placebo patch. The solution either contains AVL-3288 (3 mg) or is inactive diluent only. Over the 4 test sessions, each participant will be tested with Placebo + Placebo, Nicotine + Placebo, Placebo + AVL-3288, and Nicotine + AVL-3288, in a 2x2 factorial design. The sequence of test conditions will be only known to the statistician and pharmacist and counterbalanced across subjects.

02

Conditions studied

  • Cognitive Change

Keywords

  • nicotine
  • positive allosteric modulator
  • attention
  • cognition
03

In context

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.

Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21-50 years.
  • Male or female willing to use qualified methods of for the study duration and up to 2 months after its end. Qualified methods are: intrauterine device, condoms, oral contraceptives, surgical sterilization of the subject or the partner at least one year in advance, or status of the female defined as at least two years without menstruation.
  • No exposure to any nicotine-containing product in the last year.
  • Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.
  • Normal or corrected to normal vision (at least 20/80).
  • Body weight 110-220 lbs.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding.
  • DSM Axis I mood, anxiety or psychotic disorder.
  • Drug or alcohol abuse or dependence currently or in the last 2 years.
  • Cardiovascular or cerebrovascular disease, such as history of myocardial infarction and ischemia, heart failure, angina, stroke, severe arrhythmias, or abnormalities (see below).
  • Uncontrolled hypertension (resting systolic BP >150 or diastolic >95 mm Hg).
  • Hypotension (resting systolic BP below 90 or diastolic below 60).
  • Significant kidney or liver impairment.
  • Moderate to severe asthma.
  • Type I diabetes.
  • Gastrointestinal illness.
  • Use of any prescription or over-the-counter medication except or non-steroidal antiinflammatory drugs on an as-needed basis.
  • History of or current neurological illnesses, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome.
  • Learning disability, mental retardation, or any other condition that impedes cognition.
  • Any surgeries requiring full anesthesia scheduled within 2 weeks of any of the study test sessions.
  • Inability to perform the Rapid Visual Information Processing Task.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Nicotine - AVL-3288 Interaction Study

    Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.

    Drug: Placebo · Drug: Nicotine · Drug: AVL-3288 · Drug: Nicotine + AVL-3288

Interventions

  • DrugPlacebo

    placebo skin patch and placebo oral solution

  • nicotine skin patch (7 mg/24 hrs) and placebo oral solution

  • DrugAVL-3288

    placebo skin patch and AVL-3288 oral solution (3 mg)

  • DrugNicotine + AVL-3288

    Drug page: NicotineStudies of NicotineNicotine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)

06

What researchers measure

Primary outcomes

  1. Spatial Attentional Resource Allocation Task reaction time

    average reaction time of trials with a signal detection response

    Time frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day

  2. Spatial Attentional Resource Allocation Task omission errors

    percentage of trials on which no response was registered

    Time frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day

  3. Rapid Visual Information Processing Task signal detection

    signal detection index based on hit rate and false alarm rate

    Time frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day

  4. Rapid Visual Information Processing Task reaction time

    average reaction time on trials with a correct response

    Time frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day

  5. Change Detection Task accuracy

    % of correct responses

    Time frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day

  6. Change Detection reaction time

    average reaction time across trials

    Time frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day

Secondary outcomes

  1. Vital signs: blood pressure

    mm Hg

    Time frame: hourly for 8 hours on each test day

  2. Vital signs: heart rate

    beats per minute

    Time frame: hourly for 8 hours on each test day

  3. ECG

    QTc interval

    Time frame: Before and 4 hours after ingestion of oral solution on each test day

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study data will be made available, in de-identified form, to Anvyl LLC (Irvine, CA).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2018; primary completion for Feb 2019, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2017
First posted
Sep 13, 2017
StartEst.
May 2018
Primary completionEst.
Feb 2019
CompletionEst.
Feb 2019
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03281694
Responsible party
Robert Buchanan (Professor, Director Maryland Psychiatric Research Center, University of Maryland, Baltimore) — Principal investigator
First posted
Sep 13, 2017
Start date
May 2018 (estimated)
Primary completion
Feb 2019 (estimated)
Completion
Feb 2019 (estimated)
Last update
Nov 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion